The aim of this pilot study was to exploit the graft-versus-tumor potential of allogeneic transplants while improving safety of the procedure. Twelve patients with advanced hematological malignancies and solid tumors underwent a low intensity conditioning regimen (fludarabine and cyclophosphamide) followed by an allogeneic peripheral blood stem cell transplantation. The median time to achieve an absolute neutrophil count of more than 0.5 ؋ 10 9 /l and an untransfused platelet count of more than 20 ؋ 10 9 /l was 15 and 14 days, respectively. The main extra-hematological toxicities were mucositis and infections. Acute graft-versus-host (GVHD) disease was experienced by 62% of evaluable patients (grade II/B or III/C 80%) responsive to steroids. Extensive chronic GVHD was observed in 62% of patients. Non-relapse transplant-related mortality by day +30 was observed in three patients (25%). Eight out of 12 patients were full donor chimeric by day +100. One patient showed a mixed chimerism at day +37 when he died from progressive disease. One patient was in complete remission (CR) before allogeneic transplantation, and after transplantation four patients achieved CR and four experienced progressive disease. Our study confirms that a low intensity conditioning regimen for allogeneic stem cell transplantation is feasible and effective in heavily pretreated patients. Bone Marrow Transplantation (2002) 30, 207-214. doi:10.1038/sj.bmt.1703626 Keywords: low intensity conditioning regimen; allogeneic transplantation; immunotherapy Allogeneic stem cell transplantation is considered the treatment of choice for a number of acute and chronic hematological malignancies and some congenital diseases.
Although a substantial number of these patients can be cured, procedure-related toxicity is considerable and largely limits its application to recipients aged less than 50 years or those otherwise destined to die due to progressive malignancy. New strategies are therefore necessary to reduce toxicity while simultaneously enhancing the immunological effects of allogeneic transplantation. Various 'non-myeloablative' allogeneic transplantation approaches have been adopted in order to exploit the graft-versus-tumor potential while improving the safety of the procedure, and a number of studies have shown the feasibility to reduce the intensity of conditioning regimens without compromising hematopoietic recovery or the establishment of complete or mixed chimeras. The supposedly low toxicity of these regimens, the sensitivity of some solid tumors to an immunological approach, and the poor prognosis of conventional therapies, provided the impetus to also treat solid tumors with allogeneic stem cell transplantation. [1] [2] [3] Three factors led to use of this approach: the high activity of donor lymphocyte infusions (DLI) in patients relapsing after conventional allogeneic transplantation, 4 the high immunosuppressive activity of purine analogues, 5 and the use of peripheral blood stem cells containing four to seven times the number of progenitor CD34 + cells, 10-100 times the number of immunocompetent cells, 6 and a higher number of a subset of dendritic cells (DC2). 7 Furthermore, despite the higher number of T lymphocytes, allo-PBSC is not complicated by a higher rate of acute graft-versus-host disease (GVHD), possibly because of growth factorinduced cytokine Th-2 polarization, 8 high IL-10 levels 9 and/or the higher number of DC2 mainly inducing a Th-2 response. 7 However, concerns have been expressed about the incidence of chronic GVHD, which has been reported to be higher after peripheral stem cell transplantation by some 10 but not all authors. [11] [12] [13] The CD34 + cell dose is 3-4 log higher in allo-PBSC than bone marrow transplantation. 6 Consequently, there is more rapid hematopoietic engraftment (in terms of neutrophil and platelet recovery) 10, 11 and immunological reconstitution. 14 However, the stem cell dose is not the only factor explaining these results because peripheral CD34
+ cells express CD8, as they do class I and II HLA, but not the co-stimulation molecules that have 'veto' activity on residual host T lymphocytes. 15 The establishment of complete chimerism is considered to be indispensable for the eradication of the malignant clone in leukemic patients, but the published data are not so clear. 16 'Mixed chimerism', which implies tolerance between donor and recipient, may have a protective effect on GVHD. 17, 18 However, as this tolerance may also extend to neoplastic cells, mixed chimerism can also be considered an intermediate phase to further stimulate the immunological reaction. 19 We report the results of a study of patients with different advanced neoplasms who were treated using a low intensity conditioning regimen followed by peripheral allogeneic stem cell transplantation.
Materials and methods
Twelve patients with HLA-identical siblings (seven males and five females with a median age of 36.5 years: range 22-53) gave their informed consent to this protocol between July 1999 and November 2000 ( Table 1 ). All of the patients had advanced or refractory hematological (7) or solid tumors (5): three (Nos 1-3) had relapsed after highdose chemotherapy (HDC) supported by autologous stem cell transplantation; four (Nos 6, 8, 10 and 12) had received one course of HDC as induction chemotherapy; four had progressive disease (PD) and one was in partial remission (PR) after several lines of conventional chemotherapy. At Alive PR +175 AC, End, m-CAPEC, HD-PAM HD = Hodgkin's disease; NHL-HG = non-Hodgkin's lymphoma, high grade; P-LLC = prolymphocytic chronic leukemia; Desmo = metastatic desmoplastic tumor; pPNET = metastatic primitive peripheral neuroectodermic tumor; Breast = metastatic breast cancer; Renal = metastatic renal cancer; NE = not evaluable; Ex = extensive; CR = complete remission; PR = partial remission; PD = progressive disease. the time of enrolment, six (50%) had PD, five (42%) were in PR, and only one (8%) was in complete remission (CR).
Conditioning regimen
All but one of the patients received a non-myeloablative conditioning regimen consisting of fludarabine 25 mg/m 2 once daily for 5 days (from day Ϫ6 to day Ϫ2) and cyclophosphamide 60 mg/kg once daily for 2 days (days Ϫ3 and Ϫ2); patient No. 5 received melphalan 140 mg/m 2 instead of cyclophosphamide ( Figure 1 ).
GVHD prophylaxis
GVHD prophylaxis was tailored on the basis of the results of immunosuppression on disease status, and consisted of a continuous infusion of cyclosporine (CsA) from day Ϫ1 (3 mg/kg/day), supplemented by a short course of methotrexate (day +1 = 15 mg/m 2 , days +3, +6, +11 = 10 mg/m 2 ) in seven patients. The Seattle 20 and IBMTR scores 21 were used to evaluate aGVHD: patients with Glucksberg grade II-IV and IBMTR grade B-D aGVHD were treated with a methylprednisolone 2 mg/kg bolus followed by 1 mg/kg every 12 h. Response was evaluated after 3 days and, in the case of a CR, the steroid dose was tapered by 10 mg/day. Chronic GVHD (cGVHD) was classified as extensive or localized. Initial immunosuppression, its tailoring on the basis of clinical response, and chimerism status are shown in Figure 1 . Eight donor/recipient pairs were sexmismatched and five were ABO-mismatched (3 minor, 1 major/minor, and 1 major). 
Supportive care
No growth factors or antimicrobial prophylaxis were used after transplantation but, if the absolute neutrophil count was Ͻ0.5 ϫ 10 9 /l on day +15, daily rhu-G-CSF was started (5 g/kg/day). Any fever during the period of aplasia was treated according to established guidelines. 22 Herpes virus prophylaxis was started on day +1, and consisted of acyclovir 500 mg i.v. every 8 h: at the time of hospital discharge, patients were prescribed oral acyclovir 800 mg/day. Pneumocystis carinii prophylaxis (PCP) consisted of trimethoprim-sulphamethoxazole (one tablet every 12 h) during the conditioning regimen, stopped on day Ϫ1, and then resumed at the time of hematopoietic reconstitution during immunosuppression (one double strength tablet every 12 h 2 days per week).
Prophylactic platelet transfusions were administered in order to maintain a platelet count of more than 10 ϫ 10 3 /mm 3 ; red cells were transfused when hemoglobin levels fell below 7 g/dl. All products were irradiated and filtered.
Flow cytometry
An aliquot of 0.5-1 ϫ 10 6 of peripheral blood cells and leukapheresis product was incubated at 4°C for 20 min with 20 l of the fluorescein isothiocyanate-conjugated monoclonal antibodies (mAbs) against CD3, CD5, CD1a, CD33, or HLA-DR (Becton Dickinson, Franklin Lake, NJ, USA), Bone Marrow Transplantation phycoerythrin-conjugated monoclonal antibodies against CD4, CD8, CD19, CD34, CD16+56 (Becton Dickinson) and peridin chlorophyll protein-conjugated mAb recognizing CD45 (Becton Dickinson); then Auto Lyse plus was added and washed twice. Flow cytometry was performed using a FACScan (Becton Dickinson) software System II. The flow rate was kept between 200 and 400 cells. Debris was gated out using the forward scatter discriminator, and the leukocytes gated on the basis of their forward/side scattering characteristics. The positive cells were identified on a dot-plot of log fluorescence vs side as a distinct population positioned above the isotypic control-stained cells, and had the same side scatter as mononuclear cells: 10 6 cells were usually evaluated. The results were expressed in percentage of the positive cells and positive cells/l.
Chimerism evaluation
Chimerism was assessed by means of standard cytogenetic or FISH procedures in sex-mismatched, or PCR informative sequences in sex-matched pairs.
Donor mobilization
HLA-identical siblings were mobilized by means of subcutaneous of glycosylated rhu-G-CSF 10 g/kg/day every 12 h from day Ϫ4 to leukapheresis. The stem cells were har-vested using a Cobe Spectra (Denver, CO, USA) 3000 device on day +5, and the target stem cell dose was fixed at 4 ϫ 10 6 CD34 + /kg of recipient. Stem cells were freshly reinfused without any manipulations.
Statistical methods
Results were statistically analyzed using the Intercooled Stata 6.0 program (http:\\www.stata.com). Continuous variables were expressed as median values and compared using a t-test for paired data; the categorical data were expressed as proportions. A P value of Ͻ0.05 was considered significant. Freedom from progression (FFP) and overall survival (OS) were calculated from the date of enrolment to the date of the first sign of progression or the date of death, in accordance with the Kaplan-Meier method.
Results

Clinical results
Clinical results are shown in Table 1 . The median followup was 200 days (range 150-570). Five patients (40%) died: three before day +30 (one multiorgan failure, one septic shock, one cardiac arrest), and two after day +30 because of progressive disease. Of the seven patients who are still alive (60%), four are in CR, one in PR, and two have PD. The estimated overall survival of the patients as a whole is 50% after 400 days (Figure 2 ). The estimated median overall survival of the patients with lymphoid malignancies has not been reached (Figure 3) . It is interesting to note that four heavily pretreated patients achieved a long-lasting CR.
The nine female and three male donors had a median age of 48 years (range 23-56), and were all mobilized by means of two s.c. doses of glycosylated rhuG-CSF, which were well tolerated and did not require analgesia. All leukaphereses were undertaken using peripheral access. On day +5, the median number of white cells was 55.1 ϫ Table 2 ). The median number of circulating CD34 + cells detected on days +5 and +6 were 93/l and 59/l, respectively. The target stem cell dose was harvested by means of a single apheresis in five donors (41%) and two aphereses in seven (59%). Table 3 shows the graft composition: the only difference in cell subtype levels between days +5 and +6 concerned CD8 + cells (P = 0.01). Eight donor/recipient pairs were sex-mismatched. Five donor/recipient pairs were ABO/mismatched (three minor, one major/minor, one major).
Hematological reconstitution
The median number of reinfused CD34
+ cells was 4.7 ϫ 10 6 /kg in recipients (range 3.9-7.4). In evaluable patients (9/12), hematological reconstitution was good with a median time to neutrophil recovery (Ͼ0.5 ϫ 10 9 /l) of 15 days (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , and a median time to platelet recovery (Ͼ20 ϫ 10 9 /l) of 14 days (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The mean number of red cell and platelet units transfusion was 5 and 37, respectively. We did not observe hemolytic anemia or pure red cell aplasia in ABO mismatched recipients.
Extra-hematological toxicity
The conditioning regimen was well tolerated in all cases. One patient developed mild veno-occlusive disease on day +12 (treated with prostacyclin E1), and hemorrhagic cystitis on day +15 (treated by means of surgical decortication). Severe (NCI grade III/IV) mucositis was recorded in 4/11 evaluable patients (36%). During aplasia, the blood cultures of 5/11 patients (45%) were positive for Gram+ (Staphylococcus coagulase negative and Streptococcus oralis) and GramϪ (Pseudomonas aeruginosa and Escherichia coli); in the case of one patient, Gram+ and GramϪ bacteria were simultaneously cultured. One patient with a Pseudomonas aeruginosa strain resistant to all of the antibiotics tried, died of septic shock. Standard X-ray of one patient revealed basal pneumonia not documented microbiologically, which regressed after broad-spectrum antibacterial and antifungal therapy. One patient developed neurological symptoms associated with brain lesions detected by nuclear magnetic resonance; spinal fluid analysis failed to reveal any microbiological causes, but the clinical symptoms and brain lesions disappeared after cyclosporine was discontinued.
Cytomegalovirus reactivation without clinical disease was detected in three patients (days +45, +62, +320), and was successfully treated by a 14-day course of gancyclovir.
GVHD
aGVHD was observed in 5/8 patients (62%), which was classified as Glucksberg grade II/III and IBMTR B/C in four. The patients received methylprednisone at a standard i.v. dose of 2 mg/kg/day, with complete remission in all cases. cGVHD was evaluable in eight patients who survived after day +100, five of whom (62%) developed extensive cGVHD treated with steroids and/or CsA. One patient developed extensive oral and hepatic cGVHD that was resistant to steroids and aziothioprine, but regressed after treatment with mycophenolate mofetil and steroids.
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Chimerism
Chimerism was analyzed using standard cytogenetic, FISH or molecular biology procedures. Eight patients were evaluable for chimerism analysis on day +30, five of whom (63%) showed full donor chimerism and three (37%) mixed chimerism (which was predominantly donor-based in two cases). All seven evaluable patients showed full donor chimerism between day +70 and day +100 (Figure 4) .
Discussion
Over the last few years, an increasing body of experimental and clinical evidence has shown that allogeneic stem cell transplantation, which was initially developed as a means of delivering supralethal chemotherapy and radiotherapy doses for the treatment of hematological malignancies, has a mechanism of action that is closely related to an associated immune-mediated graft-versus-tumor effect. 23 However, the potential therapeutic benefits of allogeneic transplantation were counterbalanced by immediate and delayed toxicities mainly due to the conditioning regimen-related myeloablative effects.
Several non-myeloablative conditioning regimens have therefore been developed with the aim of exploiting this graft-versus-tumor potential and simultaneously reducing toxicity and improving the safety of the procedure in order to make it possible to treat patients whose age or concomitant medical conditions contraindicate the use of classical allogeneic transplants. 12, [24] [25] [26] [27] [28] [29] [30] However, despite their ambitious aims of reducing toxicity, creating sufficent immunosuppression to avoid a hostversus-graft reaction and GVHD, and inducing complete chimerism, these regimens do not seek to achieve full donor chimerism themselves because of the possibility of using DLI to convert mixed to complete chimerism. Although some recipients with mixed chimerism may show a clinical response, 19 there is no doubt that full donor chimerism is an important factor in ensuring a tumor response. Nevertheless, mixed chimerism is a state of reciprocal tolerance that has a protective effect against GVHD. 17, 18 The possibility of establishing a graft-versus-tumor effect against non-hematological malignancies is of great interest. It is now clear that such regimens can lead to the sustained regression of metastatic renal cancer, 1,2 and there is preliminary evidence of a graft-versus-tumor effect in breast cancer. 3, 31 Although further studies are required to determine whether the clinical results in the case of solid tumors are sufficient to justify the added morbidity, CR can beachieved even by patients with a poor prognosis.
All of our patients had a poor prognosis because their disease was refractory to conventional or high-dose chemotherapy (only one was in complete remission), but there were three post-transplant CRs. Of particular interest is the case of a patient with inflammatory breast cancer and bone metastases who was progressiong after conventional chemotherapy but achieved CR with a normalized bone scan and MRI, thus extending the graftversus-tumor effect previously reported in the case of liver metastases. 3, 31 Only one responding patient did not develop acute or chronic GVHD (Table 1) , thus suggesting that GVHD and graft-versus-tumor are not clinically dissociable, as has been reported in advanced renal and breast cancer.
We found that the use of a conditioning regimen combining fludarabine and cyclophosphamide not only led to major marrow suppression and a relatively long aplastic phase, but also had considerable immunosuppressive activity, as is demonstrated by the absence of graft rejection and the fact that all of the evaluable patients showed complete chimerism between days +70 and +100. It seems that the use of lower doses of fludarabine plus cyclophosphamide, preceded by high-dose chemotherapy and autologous rescue, 32 in addition to growth factor significantly reduces the myeloablative effect without affecting outcome. Infections are relatively frequent and one patient died of septic shock. This could be related to the long aplasia period, poor performance status, and high incidence of aGVHD. Furthermore, this result could be explained by the absence of antibiotic and/or antimycotic prophylaxis. This complication should be formerly studied as suggested by Martino et al. 33 Treatment-related mortality in our series (25%) is higher than the approximately 15% reported in previous studies, but this may be related to the selection of patients in very poor condition, as reported by Giralt et al. 34 GVHD remains a key problem. Our post-transplant immunosuppression regimen consisted of CsA plus a short course of methotrexate in the patients not in progression at transplant, and CsA alone in others. Although no grade IV episodes or related deaths were recorded, aGVHD occurred in 62% of our cases; the frequent occurrence of cGVHD was in line with the data previously reported for peripheral stem cell transplantation. 10 Graft composition (Table 3) was slightly different compared to data reported by others. 13 The most relevant difference concerns the number of CD3 + , CD4 + and CD8 + cells, which were fewer in our donors. We do not have immediate explanations for this result.
In conclusion, our data confirm that allogeneic stem cell transplantation using a reduced intensity conditioning regimen is an appealing approach that can also be used for patients with poor prognosis malignancies. Its toxicity seems to be less than that of conventional myeloablative allogeneic transplantation. However, some important issues still have to be solved: the best conditioning regimen, optimal immunosuppressive therapy, appropriate selection of patients with neoplastic disease, and tumour aggressiveness-related approach. In particular, it seems to be advisable to use high-dose induction therapy and autologous stem cell reinfusion followed by a nonmyeloablative allogeneic transplant with a less aggressive conditioning treatment for rapidly growing tumors, 32 and up-front non-myeloablative allogeneic transplants with more aggressive conditioning regimens (as in our series) for indolent malignancies.
Finally, it is clear that we have entered a promising new technology era that could revolutionize the clinical use of allogeneic transplantation, but this will depend on our ability to answer the questions raised by these new concepts in a relatively short time.
